Hulio (Adalimumab)
Autoimmune Diseases
ApprovedCommercial
Key Facts
About Biocon
Founded in 1978 by Kiran Mazumdar-Shaw, Biocon has evolved from a garage startup into Asia's premier biotechnology enterprise with a focus on affordable healthcare solutions. The company operates through three key subsidiaries: Biocon Biologics (biosimilars), Biocon Pharma (generics), and Syngene (research services), serving patients in over 120 countries. Biocon has established itself as a pioneer in insulin manufacturing and biosimilar development, with multiple products approved by stringent regulatory authorities including FDA and EMA.
View full company profileTherapeutic Areas
Other Autoimmune Diseases Drugs
| Drug | Company | Phase |
|---|---|---|
| Inflammation & Immunology Programs | Pfizer | Phase 2/3 |
| ARGX-118 | Argenx | Phase 1 |
| Adalimumab biosimilar (IBI303) | Innovent Biologics | Approved |
| Undisclosed ImmTAAI candidates | Immunocore | Preclinical |
| BHV-1100 (IgG degrader) | Biohaven | Preclinical |
| Bispecifics | Shattuck Labs | IND-Enabling |
| Preclinical Pipeline | Autolus Therapeutics | Pre-clinical |
| FT839 | Fate Therapeutics | Phase 1 |
| IMP761 | Immutep | Phase 1 (planned) |